Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders - Summary - MDSpire
Advertisement
Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders
To explore challenges in implementing patient-reported outcome measures (PROMs) for myeloma, lymphoma, and leukaemia patients undergoing CAR-T and BsAbs therapies, and to identify opportunities for optimizing PROM use, including improving alignment, consistency, and interpretability of PROM data.
Key Findings:
Challenges include logistical issues post-CAR-T infusion and diverse side effects of BsAbs, such as nausea and neurotoxicity.
Stakeholders face difficulties in balancing expectations and determining what to measure.
Generic and disease-specific PROM instruments may overlook critical patient experiences.
Interpretation:
Clearer guidance and systematic inclusion of patient-important domains are essential for improving PROMs, understanding the impact of CAR-T and BsAbs treatments, and informing regulatory decision-making.
Limitations:
Limited availability of PROMs specifically designed for CAR-T and BsAbs, which may hinder comprehensive data collection.
Current measures may not capture the full spectrum of patient experiences, potentially affecting treatment evaluations.
Conclusion:
Improving PROMs through high-frequency assessments and comprehensive reporting will enhance understanding of treatment impacts on patients' quality of life.
